Yuhan Corp - Company Profile
Powered by 
All the sales intelligence you need on Yuhan Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Yuhan Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Yuhan Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Yuhan Corp (Yuhan) discovers, develops, manufactures and markets pharmaceutical products. The company offers APIs and intermediates for antibiotic, antiviral, antifungal, anti-thrombotic, anti-inflammatory, anti-diabetic, and anti-hyperlipidemics. The company offers finished goods for the treatment of hypertension, coronary artery disease, hyperlipidemia, cerebral thrombosis and other diseases. Yuhan provides custom synthesis services for other pharmaceutical and biopharmaceutical companies. It offers active pharmaceutical ingredients (API) and finished products in domestic as well as international markets. Yuhan operates R&D and manufacturing facilities in Seoul. The company offers its products and services through its sales and distribution branches. Yuhan is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
74, Noryangjin-Ro, Dongjak-Gu, Seoul, 06927
Website
www.yuhan.co.kr
Telephone
82 2 8280181
No of Employees
1,594
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
000100 (KRX)
Revenue (2024)
$1.5B
5.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
174.6%
(2024 vs 2023)
Market Cap*
$3.7B
Net Profit Margin (2024)
XYZ
159.7%
(2024 vs 2023)
* As of and is in US$
Yuhan Corp premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| APIs & Intermediates: | Custom Synthesis Service | Viread |
| Levofloxacin Hemihydrate | Supply Chain Management | Trajenta |
| Piperacillin Monohydrate | Twynsta | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In September, the company entered into an agreement Gilead Sciences to supply the active pharmaceutical ingredient (API) for HIV treatments. |
| 2025 | Contracts/Agreements | In August, the company entered into a partnership with Gilead Sciences to deliver the active pharmaceutical ingredient for hepatitis C virus treatment. |
| 2025 | Contracts/Agreements | In January, the company entered into an agreement with Bayer Korea for Bepanthen Ointment and Canesten. |
Competitor Comparison
| Key Parameters | Yuhan Corp | Green Cross Holdings Corp | Daewoong Pharmaceutical Co Ltd | Huons Global Co Ltd | Yuyu Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Seoul | Yongin | Hwaseong | Seongnam | Jecheon |
| State/Province | - | - | - | - | Seoul |
| No. of Employees | 1,594 | 170 | 1,749 | 541 | 248 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wook Je Cho | Chief Executive Officer; President; Director | Executive Board | 2021 | 70 |
| Jeong Hee Lee | Chairman | Non Executive Board | 2021 | 74 |
| Choi Young-ki | Head - Drug Research & Development, Acting | Senior Management | 2025 | - |
| Dong Jin Park | Director | Non Executive Board | - | 61 |
| Sung Gil Chi | Director | Non Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer